Agenda - October 25, 2007
Click here for Session Descriptions.
7:45-8:30 a.m. Continental Breakfast
8:30-8:35 a.m. Welcome and Overview
Richard Katz, M.D.
Professor of Medicine, Director, Division of Cardiology and the
Cheney Cardiovascular Institute,
The George Washington University School of Medicine
8:35-9:15 a.m. Morning Keynote Speaker: Genomics for Developing Biomarkers
Andrew Plump, M.D., Ph.D.
Executive Director, Cardiovascular Disease Franchise, Merck & Co.
9:15-9:55 a.m. Identifying Targets for Therapy Via Genomic Strategies
Timothy McCaffrey, Ph.D.
Professor of Biochemistry and Director,
McCormick Genomics Center,
The George Washington University School of Medicine
9:55a.m. Break
10:05-10:55 a.m. Genomics & Congestive Heart Failure
Michael R. Bristow, M.D., Ph.D.
Professor of Medicine, Division of Cardiology,
University of Colorado Health Sciences Center,
Chairman and Chief Science and Medical Officer, ARCA Discovery
10:55-11:35 a.m. Applications of Pharmacogenomics to Improve Cardiovascular Drug Safety
Raymond L. Woosley, M.D., Ph.D.
President and CEO, The Critical Path Institute
11:35-11:50 a.m. Panel Discussion
12:15-1:45 p.m. Luncheon – Continental Ballroom
The Marvin Center
The George Washington University
Luncheon Keynote Speaker: Genomics & Coronary Artery Disease
Elizabeth G. Nabel, M.D.
Director, National Heart, Lung, and Blood Institute (NHLBI)
2:00-2:40 p.m. Markersand Mediators of Atherosclerosis revealed by Genomic Analysis of Circulating Cells
Paul Hwang M.D., Ph.D.
Principal Investigator, Cardiology Branch National Heart, Lung, and Blood Institute
2:40-3:20 p.m. Gene Variants Predict Risk of CHD and Clinical Benefit from Statin Therapy
James J. Devlin, Ph.D.
Director, Cardiovascular Research, Celera
3:20 p.m. Break
3:40-4:20 p.m. Genotypic and Phenotypic Markers of CAD
Robert Roberts, M.D.
President and CEO University of Ottawa Heart Institute
4:20-4:50 p.m. Pilot Process for Biomarker Qualification at the FDA
Federico Goodsaid, Ph.D.
Genomics Group, Office of Clinical Pharmacology, Office of Translational Science,
Center for Drug Evaluation & Research
4:50-5:00p.m. Panel Discussion